Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is a source of bicarbonate precursor. It is metabolized to bicarbonate in the liver, which buffers metabolic acidosis, restoring acid-base balance.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Alternative to sodium bicarbonate for metabolic acidosis when lactate metabolism is intact,Fluid and electrolyte replenishment,Mild to moderate metabolic acidosis
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous infusion: The typical adult dose is 300-500 m L of 1/6 Molar sodium lactate solution (approximately 167 m Eq/L each of sodium and lactate, 1 L contains 167 m Eq of sodium and lactate) administered as a continuous intravenous infusion at a rate of 0.5-2.5 m L/kg/hour, adjusted based on the severity of acidosis and clinical response. Maximum infusion rate: 2.5 m L/kg/hour.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
30–60 minutes for lactate conversion; bicarbonate component determined by CO2 excretion.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Primarily hepatic gluconeogenesis; lactate is converted to glucose via the Cori cycle, or oxidized to carbon dioxide and water; metabolism requires adequate liver function.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Primarily renal as bicarbonate and lactate; <5% unchanged.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Negligible (<1%); does not bind significantly to plasma proteins.
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
0.4-0.6 L/kg; distributes primarily in extracellular fluid.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Intravenous: 100%
Intravenous: 100%.
Contraindicated in severe renal dysfunction (e GFR < 30 m L/min/1.73 m²) due to risk of hypernatremia and volume overload. In patients with e GFR 30-59 m L/min/1.73 m², use with caution, reduce infusion rate by 25-50%, and monitor serum sodium and fluid balance closely.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Contraindicated in severe hepatic impairment (Child-Pugh Class C) due to impaired lactate metabolism. In Child-Pugh Class A or B, use with caution, reduce infusion rate by 50%, and monitor arterial blood gases and lactate levels frequently.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Intravenous infusion: Administer 3-5 m L/kg of 1/6 Molar sodium lactate as a bolus over 30 minutes, followed by a continuous infusion at 0.5-1 m L/kg/hour, titrated to correct metabolic acidosis. Maximum infusion rate: 2 m L/kg/hour.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Use with caution due to decreased renal function and higher risk of fluid overload. Start at lower end of dosing range (0.5-1 m L/kg/hour) and monitor serum electrolytes, fluid balance, and renal function closely. Contraindicated if e GFR < 30 m L/min/1.73 m².
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
None.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Use with caution in patients with impaired liver function, lactic acidosis, or conditions predisposing to lactic acidosis (e.g., shock, hypoxia). Monitor serum electrolytes and acid-base status. Risk of hyperlactatemia if metabolism is impaired.
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Severe lactic acidosis, hyperlactatemia, severe hepatic impairment, metabolic alkalosis, hypocalcemia, and patients with known hypersensitivity to sodium lactate.
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No specific food interactions known. However, patients on sodium-restricted diets should account for the sodium content of this solution (approximately 167 m Eq/L).
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Sodium lactate is a normal metabolic intermediate and component of IV fluids. No teratogenic effects are known at therapeutic doses. Risk cannot be ruled out in first trimester, but no specific fetal risks are associated with maternal administration of this physiologic compound.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Sodium lactate is a normal constituent of breast milk. Exogenous administration is unlikely to significantly alter milk levels. M/P ratio not established. Considered compatible with breastfeeding.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
No dose adjustment required. Physiologic increases in plasma volume during pregnancy may dilute infused fluids, but standard dosing based on clinical status is appropriate.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
Sodium lactate 1/6 Molar is a crystalloid solution providing approximately 167 m Eq/L of sodium and 167 m Eq/L of lactate. It is metabolized to bicarbonate in the liver, making it useful for correcting metabolic acidosis, especially in patients with lactic acidosis or those unable to tolerate bicarbonate due to hypocalcemia or hypercapnia. Monitor serum electrolytes, lactate levels, and acid-base status. Avoid in severe liver dysfunction as conversion to bicarbonate is impaired. Use with caution in patients with heart failure or renal impairment due to sodium load. For intravenous use only; do not administer with calcium-containing solutions due to precipitation risk.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This medication is a solution that helps correct acid buildup in your blood.,It will be given through a vein (intravenously) by a healthcare professional.,You may need frequent blood tests to monitor your electrolyte levels and acid-base balance.,Inform your doctor if you have liver disease, heart failure, or kidney problems.,Report any signs of fluid overload such as shortness of breath, swelling in the ankles or legs.,Do not take any other medications or supplements without consulting your doctor.,This solution contains sodium; discuss any dietary sodium restrictions with your healthcare provider.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is a source of bicarbonate precursor. It is metabolized to bicarbonate in the liver, which buffers metabolic acidosis, restoring acid-base balance.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is: Intravenous infusion: The typical adult dose is 300-500 m L of 1/6 Molar sodium lactate solution (approximately 167 m Eq/L each of sodium and lactate, 1 L contains 167 m Eq of sodium and lactate) administered as a continuous intravenous infusion at a rate of 0.5-2.5 m L/kg/hour, adjusted based on the severity of acidosis and clinical response. Maximum infusion rate: 2.5 m L/kg/hour.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is classified as Category C. Sodium lactate is a normal metabolic intermediate and component of IV fluids. No teratogenic effects are known at therapeutic doses. Risk cannot be ruled out in first trimester, bu. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.